Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBIT: 2012-2024

Historic EBIT for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$301.7 million.

  • Ascendis Pharma A's EBIT rose 112.10% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.3 million, marking a year-over-year increase of 54.37%. This contributed to the annual value of -$301.7 million for FY2024, which is 38.44% up from last year.
  • As of FY2024, Ascendis Pharma A's EBIT stood at -$301.7 million, which was up 38.44% from -$490.1 million recorded in FY2023.
  • Ascendis Pharma A's EBIT's 5-year high stood at -$301.7 million during FY2024, with a 5-year trough of -$573.2 million in FY2022.
  • Over the past 3 years, Ascendis Pharma A's median EBIT value was -$490.1 million (recorded in 2023), while the average stood at -$455.0 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 166,402.71% in 2020, then skyrocketed by 38.44% in 2024.
  • Over the past 5 years, Ascendis Pharma A's EBIT (Yearly) stood at -$377.5 million in 2020, then tumbled by 36.91% to -$516.8 million in 2021, then fell by 10.90% to -$573.2 million in 2022, then grew by 14.49% to -$490.1 million in 2023, then surged by 38.44% to -$301.7 million in 2024.